![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Daclatasvir Exposure Does Not Explain Lower Sustained Virologic Response Rates in Cirrhotic Patients With HCV Genotype 3 Following 12 Weeks of Daclatasvir Plus Sofosbuvir Treatment
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Eley T, Raybon J, Wang R, Rana K, Huang S-P, Gandhi Y, Cirincione B, LaCreta F, Garimella T
Bristol-Myers Squibb Research and Development, Princeton, NJ
![AASLD1.gif](../images/120415/121415-2/AASLD1.gif)
![AASLD2.gif](../images/120415/121415-2/AASLD2.gif)
![AASLD3.gif](../images/120415/121415-2/AASLD3.gif)
![AASLD4.gif](../images/120415/121415-2/AASLD4.gif)
![AASLD5.gif](../images/120415/121415-2/AASLD5.gif)
![AASLD6.gif](../images/120415/121415-2/AASLD6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|